Angiogenesis in melanoma: an update with a focus on current targeted therapies

被引：57
作者：
Jour, George [1 ]
Ivan, Doina [1 ]
Aung, Phyu P. [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Unit 0085,1515 Holcombe Blvd, Houston, TX 77030 USA
来源：
JOURNAL OF CLINICAL PATHOLOGY | 2016年 / 69卷 / 06期
关键词：
ENDOTHELIAL GROWTH-FACTOR; PRIMARY CUTANEOUS MELANOMA; MATRIX-METALLOPROTEINASE INHIBITOR; METASTATIC MALIGNANT-MELANOMA; VON-WILLEBRAND-FACTOR; PRIMARY TUMOR-GROWTH; STAGE IV MELANOMA; PHASE-II; IN-VIVO; VASCULOGENIC MIMICRY;
D O I：
10.1136/jclinpath-2015-203482
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
Angiogenesis plays a crucial role in melanoma metastasis and progression. In recent years, numerous studies have investigated the prognostic and clinical significance of this phenomenon, and the development of molecular techniques has enabled us to achieve a better understanding of angiogenesis in melanoma. Herein, we review the current state of knowledge regarding angiogenesis in melanoma, including the pathophysiological, histological and immunohistochemical aspects of this phenomenon. We also review the molecular pathways involved in angiogenesis and the interplay between different components that might be manipulated in the future development of efficient targeted therapies. Recently developed targeted antiangiogenic therapies in clinical trials and included in the treatment of advanced-stage melanoma are also reviewed.
引用
收藏
页码：472 / 483
页数：12
相关论文
共 134 条
[1]   Phase II Trial of Temozolomide and Sorafenib in Advanced Melanoma Patients with or without Brain Metastases [J].
Amaravadi, Ravi K. ;
Schuchter, Lynn M. ;
McDermott, David F. ;
Kramer, Amy ;
Giles, Lydia ;
Gramlich, Kristi ;
Carberry, Mary ;
Troxel, Andrea B. ;
Letrero, Richard ;
Nathanson, Katherine L. ;
Atkins, Michael B. ;
O'Dwyer, Peter J. ;
Flaherty, Keith T. .
CLINICAL CANCER RESEARCH, 2009, 15 (24) :7711-7718
[2]   MicroRNA-mediated regulation of the angiogenic switch [J].
Anand, Sudarshan ;
Cheresh, David A. .
CURRENT OPINION IN HEMATOLOGY, 2011, 18 (03) :171-176
[3]   A review of tissue inhibitor of metalloproteinases-3 (TIMP-3) and experimental analysis of its effect on primary tumor growth [J].
AnandApte, B ;
Bao, L ;
Smith, R ;
Iwata, K ;
Olsen, BR ;
Zetter, B ;
Apte, SS .
BIOCHEMISTRY AND CELL BIOLOGY-BIOCHIMIE ET BIOLOGIE CELLULAIRE, 1996, 74 (06) :853-862
[4]   Metronomics: towards personalized chemotherapy? [J].
Andre, Nicolas ;
Carre, Manon ;
Pasquier, Eddy .
NATURE REVIEWS CLINICAL ONCOLOGY, 2014, 11 (07) :413-431
[5]   Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model [J].
Arap, W ;
Pasqualini, R ;
Ruoslahti, E .
SCIENCE, 1998, 279 (5349) :377-380
[6]   Microvessel density, lymphovascular density, and lymphovascular invasion in primary cutaneous melanoma-correlation with histopathologic prognosticators and BRAF status [J].
Aung, Phyu Phyu ;
Leone, Dominick ;
Feller, John Kyle ;
Yang, Shi ;
Hernandez, Mailer ;
Yaar, Ron ;
Singh, Rajendra ;
Helm, Thomas ;
Mahalingam, Meera .
HUMAN PATHOLOGY, 2015, 46 (02) :304-312
[7]   LYVE-1, a new homologue of the CD44 glycoprotein, is a lymph-specific receptor for hyaluronan [J].
Banerji, S ;
Ni, J ;
Wang, SX ;
Clasper, S ;
Su, J ;
Tammi, R ;
Jones, M ;
Jackson, DG .
JOURNAL OF CELL BIOLOGY, 1999, 144 (04) :789-801
[8]   Expression of platelet-derived growth factor (PDGF)-A, PDGF-B and the PDGF-alpha receptor, but not the PDGF-beta receptor, in human malignant melanoma in vivo [J].
Barnhill, RL ;
Xiao, M ;
Graves, D ;
Antoniades, HN .
BRITISH JOURNAL OF DERMATOLOGY, 1996, 135 (06) :898-904
[9]  
BARNHILL RL, 1992, LAB INVEST, V67, P331
[10]  
Bennicelli J L, 1993, Exp Dermatol, V2, P186, DOI 10.1111/j.1600-0625.1993.tb00031.x
12345678910